HKSTP Crowns Overall Champion Skyland Innovation at EPiC 2023 Pitching Competition Beating Over 610 Global Startups
28.4.2023 18:11:00 EEST | Business Wire | Press release
Hong Kong Science and Technology Parks Corporation (HKSTP) today successfully held its 7th Elevator Pitch Competition (EPiC), naming Hong Kong startup, Skyland Innovation, as the overall 2023 champion, beating over 610 startups from 55 economies around the world. The signature event has partnered with the city’s leading corporations: Cathay, HSBC, MTR Lab, plus global accelerator Plug & Play, to become a true iconic mega event that has hit a global scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230428005353/en/
Mr Albert Wong, CEO of HKSTP (Centre), alongside EPiC 2023 Top 10 overall finalists. (Photo: Business Wire)
As Hong Kong’s flagship and largest pitching contest, 50 Grand Finale semi-finalists joined the city’s most eagerly anticipated pitch event this year at sky100 at the top of the International Commerce Centre in West Kowloon to re-create a real-life 60-second elevator pitch experience.
The EPiC 2023 judging panel of the region’s top entrepreneurs, investors and innovation ecosystem leaders selected Skyland Innovation from Hong Kong, as this year’s overall champion. The winner of the grand prize of US$ 90,000, helps property owners and contractors to coordinate and communicate seamlessly on construction sites through the use of robotics and AI. The local proptech is also a spinoff from the Hong Kong Center for Construction Robotics (HKCRC) within the HKSAR Government backed AIR@InnoHK research cluster located at Hong Kong Science Park.
Along with all 50 semi-finalists, Skyland Innovation also qualifies to be considered by the HKSTP Venture Fund for additional investment deals. If selected, each company can potentially receive up to a maximum investment of US$5 million.
EPiC 2023 competitors were split across the two themes of FinTech and PropTech with FinCrime Dynamics from the UK named as the overall FinTech category winner, and Skyland Innovation Company Ltd named the overall PropTech winner from Hong Kong. This year, Canvasland, a FinTech startup from Hong Kong was also voted by the public as the “My Favourite Pitcher" winner, taking away US$10,000 and 200,000 Asia Miles. The top 10 overall finalists also won US$10,000 each (Full winners and finalists list below).
Paul Chan, Financial Secretary of Hong Kong SAR, said: “Hong Kong has a strong, thriving startup ecosystem with 4000 startups, up more than 50% from 2018. Hong Kong is also a natural gateway to the GBA, which offers tremendous growth opportunities. Successful products and services will surely have an edge in the GBA, the whole of the nation and around the world. I am truly excited to be here at EPiC 2023 where startups strive to make their 60-second pitch truly count. I congratulate all the EPiC 2023 winners and invite startups from all over the world to join us in Hong Kong where the future is built.”
Sunny Chai, Chairman, HKSTP, said: “EPiC 2023 showcases the most exciting innovations from the world’s star-studded next-generation global tech ventures. Together with the Hong Kong Government's solid commitment, as reinforced by the Hong Kong I&T Development Blueprint, our city provides the ideal platform to expand into the vast Asian market. Hong Kong is also Asia’s world city and a bridge between the mainland and the world, making us a magnet for global innovation talent and enterprises.”
Albert Wong, CEO, HKSTP, said: “This year’s EPiC competition features a record international turnout and shows Hong Kong is truly back with a strong show of unicorns and soonicorns from around the world among this year’s finalists. But EPiC is more than just a competition, it is a prime example of Hong Kong’s unique ability to help startups grow fast and go beyond by providing a network of global investment opportunities and innovation talent to turn cutting-edge science, technologies, and ideas into game-changing solutions."
A magnet for global investors and innovation talent
EPiC 2023 surpassed all expectations, attracting over 610 entries from 55 countries and cities across five continents. Over 75% of contestants come from overseas, a record high proportion of overseas contestants and economies participation since 2016. Startups joining EPiC 2023 can fully leverage the largest I&T ecosystem in Hong Kong and HKSTP’s direct connections to over 1,000 investors and more than 300 corporate partners.
In addition to the EPiC final pitching contest, the 50 semi-finalists have also taken part in the "Grow Beyond Hong Kong" Immersion Programme. This exclusive 2-day programme ran from 25-26 April, immersed the EPiC 2023 semi-finalists directly into HKSTP’s innovation ecosystem. Participants will unlock growth opportunities through educational talks, business matching and networking with leading corporate partners and investors in our ecosystem.
Winners List:
|
Overall Champion |
Skyland Innovation Company Ltd. |
||
|
“My Favourite Pitcher” Winner |
Canvasland Limited |
||
|
FinTech Winner |
FinCrime Dynamics |
||
|
PropTech Winner |
Skyland Innovation Company Ltd. |
||
|
Top 10 Overall Finalists |
FinTech Finalists:
FinCrime Dynamics Homebase Ultipa VoiceAI Technologies
PropTech Finalists:
I2Cool Limited
Mimicrete VoltSafe, Inc. Skyland Innovation Company Ltd. |
Contestants Breakdown:
|
Category |
|
|
No. of applicants |
|
PropTech |
|
|
266 (43%) |
|
FinTech |
|
|
352 (57%) |
|
|
|
|
|
|
|
|
|
No. of applicants |
|
Overseas |
|
|
465 (75%) |
|
Hong Kong |
|
|
153 (25%) |
A record high proportion of overseas contestants and economies participation since 2016.
For more information on EPiC 2023, please visit: https://epic.hkstp.org/
About Hong Kong Science and Technology Parks Corporation
Hong Kong Science and Technology Parks Corporation (HKSTP) has for over 20 years committed to building up Hong Kong as an international innovation and technology hub to propel success for local and global pioneers today and tomorrow. HKSTP has established a thriving I&T ecosystem that is home to two unicorns and Hong Kong’s leading R&D hub with over 13,000 research professionals and over 1,300 technology companies focused on healthtech, AI and robotics, fintech and smart city technologies.
Established in 2001, we attract and nurture talent, accelerate and commercialise innovation and technology for entrepreneurs on their journey of growth in Hong Kong, to the Greater Bay Area, Asia and beyond. Our growing innovation ecosystem is built around our key locations of Hong Kong Science Park in Shatin, InnoCentre in Kowloon Tong and three modern INNOPARKs in Tai Po, Tseung Kwan O and Yuen Long. The three INNOPARKs are realising a vision of new industrialisation for Hong Kong. The goal is sectors like advanced manufacturing, electronics and biotechnology are being reimagined for a new generation of industry.
Through our infrastructure, services, expertise and network of partnerships, HKSTP will help establish innovation and technology as a pillar of growth for Hong Kong, while reinforcing Hong Kong’s international I&T hub status as a launchpad for global growth at the heart of the GBA innovation powerhouse.
More information about HKSTP is available at www.hkstp.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230428005353/en/
Contact information
Media Contact:
Hong Kong Science and Technology Parks Corporation
Betsy Leung
Tel: +852 2629 2300
Email: betsy.leung@hkstp.org
Edelman Public Relations
Lisa Tse
Tel: +852 3756 8632 / 6347 2009
Email: Lisa.Tse@edelman.com / Edelmanhkstppr@edelman.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom